Shuchi Nahar's Weekend Blog!

Laurus Labs : Company & Business Overview Shuchi.P.Nahar Twitter:  @shuchi_nahar  1.   Company Profile & Background Laurus Labs is a leading R&D driven pharmaceuticals company established in 2005 with its headquarters in Hyderabad. It is among the leaders in the manufacturing of Active Pharmaceutical Ingredients (APIs) for Antiretroviral (ARV) and Hepatitis C (Hep-C) formulations. Other major API segments include therapeutic areas such as Oncology, Cardiovascular, and Anti-Diabetes. ·        From a one-product company in 2010 to an Active Pharmaceutical Ingredients (APIs) company thereafter, company has now emerged as one of India’s leading manufacturers of generics APIs for various complex therapies. ·        Company is thriving on growth opportunities in formulation manufacturing, addressing the critical needs of the world’s key pharmaceutical markets. ·        Over the years, the most important enablers of this transformation has been their People, Plants, Products, and

Emerging Trends in Animal Health Care Industry SHUCHI.P.NAHAR Just like the world around us, animal health has undergone transformational change in the 21st century. Animals are receiving better care, medicines are becoming more targeted, and diseases have even been eradicated. There's no sign that this change will stop soon. Here are the four trends that will drive animal agriculture and petcare in the coming years.The niche global animal health sector is witnessing exciting growth opportunities and consolidation. On the one hand, the opportunity landscape is driven by population expansion, increased demand for animal protein, changing lifestyles and evolving habits. On the other hand, the consolidation is the result of growing compliance and complexity. The global animal health market size was valued at USD 47.1 billion in 2019 and is expected to exhibit a CAGR of 5.8% during the forecast period. The market is largely driven by a significant rise in demand for protein food and an

CDMO's to be considered as the next stepping stone for Pharma Companies... Twitter Handle: @shuchi_nahar In recent years, pharmaceutical outsourcing has grown in popularity amongst drug developers across the industry. Companies are increasingly outsourcing to contract development and manufacturing organizations (CDMOs) due to the benefits outside expertise can bring to their business. So, what are the benefits and how are current CDMO market trends shaping? Pharma CDMO's Trends The pharmaceutical industry is expected to be worth $1.5 trillion by 2021. The key trends driving this level of demand for pharmaceutical products include the world’s aging population, rising healthcare standards in developing countries, and expensive breakthrough therapies. This rapid influx of demand means that companies are faced with higher R&D costs and a need to invest in new capabilities. The demand for healthcare and innovative solutions is growing globally with chronic diseases on the rise.

Important Segments to track growth for Pharma Companies Shuchi.P.Nahar Investments in the global pharmaceuticals sector to increase to over $1,400 billion over the next three years, driven by a number of new medicines. With healthy R&D spending going forward, the Contract Research and Manufacturing (CRAMS) segment offers growth opportunities to Indian companies .  Change in regulations around generic approvals will help Indian companies to increase penetration in Chinese markets, which will improve margin expansion.  What are CRAMS ?  CRAMS is defined as the process of outsourcing research services/ product manufacturing activities to organizations which can provide the service at a low cost. CRAMS basically consists of the following two activities: contract research and contract manufacturing. CRAMS is mainly used in the Pharmaceutical and Biotechnology sectors that require extensive R&D and large-scale manufacturing facilities. It is expected that the demand for c